Combination Treatment of C16 Peptide and Angiopoietin-1 Alleviates Neuromyelitis Optica in an Experimental Model

Figure 1

Combination treatment of C16 and Ang1 improves the clinical progression of NMO, as measured by disease scoring ( in each group). versus the vehicle-treated group at the same time point. The onset of NMO symptoms in the vehicle group was at 3 days pi, and the symptoms peaked at 1 week pi and remained until 2 weeks pi. The clinical scores of the vehicle-treated rats started to decrease afterwards, and a limp tail remained at 8 weeks pi. However, animals treated with C + A displayed clinical signs of a delayed peak stage and a reduced severity at 2 weeks pi (with mild paraparesis of the hindlimb, clinical score = 5). Moreover, the clinical scores were evidently lower in the C + A-treated group than in the vehicle-treated group at each time point.